The FDA shortage designation ended. The legal landscape shifted. Here's what's actually available in mid-2026 and what you need to know before using it.
Compounded semaglutide exploded in availability from roughly 2022 through 2024, driven by persistent shortages of Ozempic and Wegovy and a legal window that allowed pharmacies to compound drugs listed on the FDA shortage list. That window has substantially closed. Understanding exactly what changed—and what remains available—requires understanding how pharmaceutical compounding law works.
Under federal law (specifically Section 503A of the Drug Quality and Security Act), compounding pharmacies can prepare customized medications for individual patients. But there's a catch: compounders generally cannot make copies of FDA-approved drugs that are commercially available—this prevents them from undercutting brand-name manufacturers on standard products.
The exception: when a drug is on the FDA's drug shortage list. During a shortage, compounders can legally prepare copies to help patients who otherwise couldn't access the drug.
Ozempic appeared on the FDA shortage list in 2022 amid unprecedented demand. This created the legal basis for hundreds of compounding pharmacies and telehealth platforms to begin offering semaglutide at dramatically lower prices. At peak availability in 2023-2024, you could access compounded semaglutide from dozens of telehealth platforms for $99-$350/month.
In early 2025, the FDA determined that semaglutide injection products were no longer in shortage and removed them from the drug shortage list. This was the legal trigger that changed everything.
With semaglutide off the shortage list:
The FDA issued warning letters to telehealth companies and pharmacies continuing to market compounded semaglutide after the shortage designation ended. Legal actions and enforcement followed.
503B outsourcing facilities (created by the Drug Quality and Security Act) operate under stricter FDA oversight than 503A pharmacies. They're required to follow Current Good Manufacturing Practices (CGMP), submit to FDA inspections, and register with FDA. They're more like small drug manufacturers than traditional pharmacies.
503B facilities have some latitude even after a shortage ends, under specific circumstances:
This 503B gray area is actively litigated. Several 503B facilities continued operating in this space after 2025, with their legal justification resting on arguments about clinical need and product differentiation. Some telehealth companies pivoted to 503B-sourced semaglutide, arguing their compounded product differs from brand-name in clinically relevant ways.
The FDA has not definitively closed this pathway, but it has signaled aggressive enforcement. The legal situation as of mid-2026 is: ambiguous, contested, and subject to change. If you're accessing semaglutide through a telehealth platform, ask explicitly whether their pharmacy is 503A or 503B and what their current legal justification is.
Hims had one of the largest compounded semaglutide programs and fought the FDA's position publicly. After the shortage removal, they pivoted their model and restructured which pharmacies supply their program. As of mid-2026, they're operating in a complicated space involving 503B partners and are involved in ongoing litigation regarding their ability to continue this business. Their pricing and availability changes frequently—check their current offering directly.
Ro (formerly Roman) similarly had to restructure their GLP-1 program. They've moved more heavily toward facilitating access to brand-name drugs with insurance, while maintaining a compounded semaglutide offering through their Body program where legally permissible.
Smaller platforms have had more varied responses—some exited the compounded semaglutide business entirely and pivoted to tirzepatide (which was removed from shortage with different timing) or brand-name drug assistance programs. Others continue operating in the 503B gray area.
| Option | Monthly Cost | Notes |
|---|---|---|
| Wegovy (brand, list price) | $1,349 | Almost no one pays this |
| Wegovy with savings card | $25 | Requires commercial insurance |
| Ozempic (brand, list price) | $935 | For T2D, not obesity indication |
| Compounded semaglutide (503B, when available) | $150–$400 | Variable; legal status complex |
| Zepbound vials (tirzepatide, cash-pay) | $399–$699 | Brand-name; clearer legal status |
Worth noting: for many cash-pay patients, Zepbound vials at $399-$699/month are now competitive with compounded semaglutide options—and they're brand-name, with clear quality control, FDA-approved manufacturing, and no legal ambiguity. The calculus has shifted.
The FDA's concern about compounded semaglutide isn't purely about pharmaceutical company market protection. There are legitimate quality and safety issues:
Brand-name Ozempic and Wegovy use semaglutide as a free base molecule. A significant number of compounding pharmacies sourced semaglutide sodium salt—a different chemical form with different molecular weight and pharmacokinetic properties. The FDA raised this in a 2024 safety communication, noting that doses calculated for the base might be incorrect when the sodium salt is used. Patients may have been receiving doses 20-30% different from what was labeled, depending on whether the compounder was calculating by mass or molar equivalents.
This is not hypothetical—it's a documented issue that contributed to dosing errors and adverse events in some patients.
The FDA's MedWatch database documented hundreds of adverse events related to compounded semaglutide between 2022 and 2025, including hospitalizations. Common issues included: severe nausea and vomiting from incorrect dosing, contamination events, and wrong-drug dispensing errors. While adverse events also occur with brand-name products, compounded preparations had issues specifically attributable to manufacturing variability.
Vials of compounded semaglutide require patients to draw the dose themselves with syringes—unlike the auto-injector pens used for Ozempic and Wegovy. Dosing errors from incorrect measurement are common among patients not accustomed to handling injectable medications. This isn't unique to semaglutide, but it's a real risk factor.
Injectable medications require sterile preparation conditions. 503A pharmacies operate in classified cleanrooms, but they're not required to meet the same standards as 503B facilities or drug manufacturers. Several contamination incidents at compounding pharmacies (not limited to semaglutide) have led to serious patient harm. The risk is manageable but not zero.
If you decide to use compounded semaglutide, here's a checklist that separates the more careful operations from the less careful:
Search the FDA's database of registered 503B outsourcing facilities (fda.gov). If the pharmacy claiming to compound your semaglutide is not on this list, it's a 503A pharmacy operating in a legally precarious position. This doesn't make it immediately unsafe, but it's information you should have.
A CoA is a third-party laboratory document confirming the identity, purity, and concentration of the drug substance used. Any legitimate compounding operation should be able to provide a CoA for their semaglutide raw material on request. If they can't or won't, that's a red flag.
Ask explicitly: "Is your semaglutide the free base or the sodium salt form?" The CoA will specify this. You want the free base, which is consistent with what brand-name products use and for which dosing is most established.
Ask whether finished product lots undergo sterility and endotoxin testing. This should be standard for any injectable compounded drug. A pharmacy unable to confirm this is cutting corners on safety-critical processes.
Verify the pharmacy is licensed in your state and has no significant disciplinary history. The National Association of Boards of Pharmacy (NABP) maintains a "not recommended" list of online pharmacies with compliance issues.
Compounded semaglutide is significantly less available than it was in 2023-2024. The major easy-access telehealth programs have either exited the space or are operating in legally uncertain territory. If you're accessing it through a telehealth platform, understand that:
For patients who used compounded semaglutide successfully and are concerned about access: this is a real issue. Work with a prescriber to establish a plan B—whether that's qualifying for brand-name assistance programs, transitioning to tirzepatide via Zepbound vials, or pursuing insurance coverage with a new prior authorization attempt.
The cost savings of compounded semaglutide were real and meaningful for many patients. The legal window that made them possible has narrowed significantly, and navigating what remains requires more due diligence than it did two years ago.
It contains the same active molecule, but it is not the same product. Brand-name Ozempic and Wegovy are manufactured to FDA standards with complete quality controls, stability testing, and sterility assurance. Compounded semaglutide is prepared by a pharmacy and varies in quality controls depending on the facility. Additionally, some compounders used semaglutide sodium salt rather than the free base form used in brand-name products, creating dosing issues.
The FDA determined that sufficient commercial supply existed to meet demand. Novo Nordisk significantly expanded manufacturing capacity for both Ozempic and Wegovy, resolving the supply constraints that had placed both drugs on the shortage list starting in 2022. Once the shortage is resolved, the legal exemption allowing compounding pharmacies to copy the drug expires.
Options depend on your situation. If you have commercial insurance, pursue prior authorization for brand-name Wegovy with your prescriber—this is now more feasible given improved supply. If you're paying cash, Zepbound vials at $399-$699/month offer brand-name tirzepatide without insurance. If income-qualified, patient assistance programs for Wegovy and Ozempic are available. Don't abruptly stop without a plan—discuss transition with your prescriber to avoid rapid weight regain.
Tirzepatide had a different shortage timeline than semaglutide. Mounjaro and Zepbound were on the shortage list, and FDA's removal of tirzepatide from that list had its own legal and timeline complications separate from semaglutide. Check current FDA shortage list status, as this evolves. The same 503A vs 503B analysis applies to tirzepatide compounding.
Calculate what brand-name GLP-1 medications would actually cost you with insurance and savings programs—you may have better options than you think.
Medical & Legal Disclaimer: The legal status of compounded semaglutide is actively evolving through FDA enforcement actions and litigation. Information in this article reflects the situation as of May 2026 and may change. This is not legal or medical advice. Consult a licensed healthcare provider before starting, switching, or stopping any medication. If you're uncertain about the legality of a compounded product you're considering, contact a healthcare attorney or your state board of pharmacy.
Compare Providers
These providers offer online consultations, licensed prescribers, and medication shipped to your door.
GLP-1 specialist. Fast evaluation, compounded semaglutide & tirzepatide, competitive pricing.
Get Started →High patient satisfaction. Compounded semaglutide at lower cost. No in-person visit required.
Get Started →Connects patients with licensed GLP-1 prescribers. Multiple medication options, ongoing support.
Get Started →Compare all GLP-1 providers → • Sponsored links. Medical evaluation required. Results vary. See full provider comparison.